Parkinson's Drug Tavapadon Wins FDA Approval, but Falls and Depression Go Untreated

Parkinson's disease has waited a long time for a new kind of dopamine drug. AbbVie's tavapadon, now approved as Juvmo, is designed to deliver the motor benefit of a dopamine agonist without the D2/D3 side effects that make the older class hard to tolerate. That is a genuine pharmacological advance. But the people who will take it live with a disease that is far wider than its motor symptoms, and the data on how Parkinson's patients actually receive care suggest the hardest problems sit outside the prescription: falls, depression and a specialist workforce too small to reach most patients. A better pill raises the stakes on the care model around it.

A First-in-Class Agonist With a Clear Motor Signal

AbbVie announced the approval on September 28, calling Juvmo the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease. It is a once-daily tablet that can be used alone in early disease or added to levodopa. Roopal Thakkar, AbbVie's chief scientific officer, described it as the first dopaminergic breakthrough for the disease in decades. The drug came to AbbVie through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, and AJMC reports projected sales of more than $5 billion, with uptake expected to be gradual pending Medicare coverage negotiations.

The TEMPO program supports the motor claim. In the two early-disease monotherapy trials, tavapadon improved combined motor and daily-living scores by about 10 points at 26 weeks while placebo scores moved less than 2 points either way. In TEMPO-3, as an add-on to levodopa, it added 1.7 hours of daily "on" time without troublesome dyskinesia, compared with 0.6 hours on placebo, and cut "off" time by 1.9 hours versus 0.9 hours. In the 85-week open-label extension, 94% of monotherapy patients never started levodopa, and AbbVie contrasts that with roughly 70% of patients on standard therapy who need a levodopa dose increase within the first year. The American Parkinson Disease Association notes that the selective design is intended to avoid the sleepiness, impulse control disorders and hallucinations linked to D2/D3 activation.

The label still asks for caution. With levodopa, the most common adverse events included dyskinesia, hallucinations and orthostatic hypotension, and the warnings cover low blood pressure and unusual urges such as compulsive gambling or shopping. The Michael J. Fox Foundation says impulse control problems appeared at lower rates than with older agonists, and its medical team cautions that newer does not always mean better for every patient. Insurance coverage, it adds, may take longer than the prescription launch.

The Symptoms the Drug Was Not Built to Treat

Orthostatic hypotension and dizziness matter more in Parkinson's than in most indications because this population already falls at extraordinary rates. A systematic review of 22 studies found that 60.5% of people with Parkinson's reported at least one fall, 39% reported recurrent falls, and recurrent fallers averaged 20.8 falls per person per year. Added "on" time can help mobility, but none of the TEMPO results reported falls as an outcome, so a motor drug is not a substitute for fall prevention. For a new agent whose label flags low blood pressure, fall risk becomes part of how it should be prescribed.

Mental health is the larger gap. A Medicare analysis published in npj Parkinson's Disease and summarized by the Parkinson's Foundation found that 53% of beneficiaries with Parkinson's experienced depression, yet only 2% received treatment from a mental health professional. Untreated depression can weigh on adherence, physical activity and quality of life, the same outcomes a new therapy is meant to improve. A therapy measured on motor scales and activities of daily living will look better in practice if the depression that drags down both is actually treated.

Most Patients Never Reach a Specialist

The same 2019 Medicare data show how thin the care pathway is. Only 9% of beneficiaries with Parkinson's received care from a movement disorders specialist, 50% from a general neurologist, and 29% from a primary care provider. Only 20% saw a physical therapist. There are about 660 movement disorders specialists in the US, and six of them practice in rural areas. Against the Parkinson's Foundation's estimate of 1.1 million Americans living with the disease, nearly 90,000 new diagnoses a year, and a combined cost of $82.2 billion in 2024, that workforce cannot carry the launch on its own.

That changes the commercial question for AbbVie and for every sponsor with a neurology pipeline. A selective agonist with a nuanced dosing story, two distinct use cases and specific safety warnings will be prescribed in large part by general neurologists and primary care physicians who see few Parkinson's patients a year. Allison Willis, MD, quoted in the foundation's release, said the analysis reveals significant gaps in access to both recommended and best-practice care. Medical education, coordinated care and support for the services around the prescription will decide how much of the TEMPO benefit shows up in real-world outcomes.

What Life Sciences Leaders Should Do Now

• Equip the prescribers who actually see patients: Build launch education for general neurologists and primary care, not only movement disorders centers, since they manage most Medicare patients with Parkinson's.
• Pair the label with a falls conversation: Give prescribers practical guidance on orthostatic blood pressure checks, balance screening and physical therapy referral when starting or adding the drug.
• Screen for depression at initiation: Support tools that make mood screening routine at the start of therapy, given the gap between 53% prevalence and 2% specialist treatment.
• Measure what patients feel, not only motor scores: Real-world studies should track falls, hospitalizations and mental health alongside "on" time, which is the evidence payers will want during coverage negotiations.
• Support care models that coordinate the team: Partnerships with health systems, telehealth neurology and integrated care programs can extend thin specialist capacity to rural and underserved patients.

Tavapadon gives people with Parkinson's a meaningful new option for movement. Whether it changes how they live will depend on whether the system around it catches the falls, treats the depression and gets more patients in front of clinicians who know the disease. Sponsors that invest in that system will see their science travel further than the label.